IP Library Granted Patent US 7,524,944
Granted Patent B2
US 7,524,944 · App. 11/015,117 · Granted Apr 28, 2009

Chimeric nucleic acids encoding polypeptides comprising CD154 and TNF-α

Assignee: Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,944
App. No.
11/015,117
Granted
Apr 28, 2009
Kind
B2
Abstract

This invention relates to genes which encode accessory molecule ligands and their use for immunomodulation, vaccination and treatments of various human diseases, including malignancies and autoimmune diseases. This invention also describes the use of accessory molecule ligands which are made up of various domains and subdomain portions of molecules derived from the tumor necrosis factor family. The chimeric molecules of this invention contain unique properties which lead to the stabilization of their activities and thus greater usefulness in the treatment of diseases. Vectors for expressing genes which encode the accessory molecule ligands of this invention are also disclosed.

Claims (9)

1. A chimeric nucleic acid molecule comprising a polynucleotide encoding a Domain consisting of Domain III of CD40 ligand lacking a matrix metalloproteinase (mmp) cleavage site and a polynucleotide that encodes Domain I, II or IV of TNF-α.

2. The chimeric nucleic acid molecule according to claim 1 , wherein the Domain III is encoded by a nucleotide sequence contained in, and selected from, the group consisting of SEQ.ID. Nos. 1, 2, and 8, wherein the molecule is modified to delete the nucleotide sequence coding for a mmp cleavage site.

3. The chimeric nucleic acid molecule according to claim 1 , wherein the TNF-α polynucleotide encodes Domain IV of TNF-α and is modified to delete the nucleotide sequence coding for a mmp cleavage site.

4. A chirneric nucleic acid molecule comprising a polynucleotide encoding a Domain consisting of Domain III of CD40 ligand lacking a matrix metalloproteinase (mmp) cleavage site and a polynucleotide that encodes Domains I, II or IV of TNF-β.

5. The chimeric nucleic acid molecule according to claim 4 , wherein the Domain III is encoded by a nucleotide sequence contained in, and selected from, the group consisting of SEQ.ID. Nos. 1, 2, and 8, wherein the molecule is modified to delete the nucleotide sequence coding for a mmp cleavage site.

6. A recombinant expression vector comprising the chimeric nucleic acid molecule of claim 1 .

7. A host cell transfected with the recombinant expression vector of claim 6 .

8. A recombinant expression vector comprising the chimeric nucleic acid molecule of claim 4 .

9. A host cell transfected with the recombinant expression vector of claim 8 .

Assignments (1)
CONFIRMATORY LICENSE Recorded Sep 18, 2008
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021549/0140 →
Continuity (3)
Continuation 0898227200 · Dec 1, 1997
Provisional Application 6003214500 · Dec 9, 1996
Related Publication 20060183199A1 · Aug 17, 2006